Joana Jesus-Ribeiro

Joana Jesus-Ribeiro

Auto-generated profile, based on publicly available information

Joana Jesus-Ribeiro

Center for Research in Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra Coimbra Portugal

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Stroke
Verified
Journal Article
Closed access
PDF file
AMAna Inês Martins
Ana Inês Martins
JSJoão Sargento-Freitas
João Sargento-Freitas
FSFernando Silva
Fernando Silva
JJJoana Jesus-Ribeiro
Joana Jesus-Ribeiro
ICInês Martins Malva Correia
Inês Martins Malva Correia
LCLuís Cunha
Luís Cunha
Background and Purpose—: Historical stroke cohorts reported a U- or J-shaped relationship between blood pressure (BP) and clinical outcome. However, these studies predated current revascularization strategies, disregarding the recanalization state of the affected arterial territory. We aimed to investigate the relationship between BP in the first 24 hours after ischemic stroke and clinical outcome in patients submitted to intravenous or intra-arterial recanalization treatments. Methods—: Consecutive patients with acute stroke treated with intravenous thrombolysis or intra-arterial therapies were enrolled in a retrospective cohort study. BP was measured on regular intervals throughout day and night during the first 24 hours after stroke onset. The mean systolic BP and diastolic BP during the first 24 hours post stroke were calculated. Recanalization was assessed at 6 hours by transcranial color-coded Doppler, angiography, or angio–computed tomography. Functional outcome was assessed at 3 months by modified Rankin Scale. Linear and quadratic multivariate regression models were performed to determine associations between BP and functional outcome for the whole population and recanalyzed and nonrecanalyzed patients. Results—: We included 674 patients; mean age was 73.28 (SD, 11.50) years. Arterial recanalization was documented in 355 (52.70%) patients. In multivariate analyses, systolic BP and diastolic BP in the first 24 hours post stroke show a J-shaped relationship with functional outcome in the total population and in the nonrecanalyzed patients. Recanalyzed patients show a linear association with functional outcome (systolic BP: odds ratio, 1.015; 95% confidence interval, 1.007–1.024; P =0.001; R 2 change=0.001; P =0.412 and diastolic BP: odds ratio, 1.019; 95% confidence interval, 1.004–1.033; P =0.012; R 2 change<0.001; P =0.635). Conclusions—: Systemic BP in the first 24 hours after ischemic stroke influences 3-month clinical outcome. This association is dependent on the revascularization status.

1 October 2017 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
JJJoana Jesus-Ribeiro
Joana Jesus-Ribeiro
ICInês Martins Malva Correia
Inês Martins Malva Correia
AMAna Inês Martins
Ana Inês Martins
MFManuel Fonseca
Manuel Fonseca
IMInês Marques
Inês Marques
LSLívia Sousa
Lívia Sousa

22 January 2021 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
JJJoana Jesus-Ribeiro
Joana Jesus-Ribeiro
LPLuís Miguel Pires
Luís Miguel Pires
JMJoão Daniel Melo
João Daniel Melo
IRIlda Patrícia Ribeiro
Ilda Patrícia Ribeiro
OROlinda Rebelo
Olinda Rebelo
JMJoana Barbosa Melo
Joana Barbosa Melo
Introduction: Focal cortical dysplasias (FCDs) are a group of malformations of cortical development that constitute a common cause of drug-resistant epilepsy, often subjected to neurosurgery, with a suboptimal long-term outcome. The past few years have witnessed a dramatic leap in our understanding of the molecular basis of FCD. This study aimed to provide an updated review on the genomic and epigenetic advances underlying FCD etiology, to understand a genotype–phenotype correlation and identify priorities to lead future translational research.Methods: A scoping review of the literature was conducted, according to previously described methods. A comprehensive search strategy was applied in PubMed, Embase, and Web of Science from inception to 07 May 2020. References were screened based on title and abstract, and posteriorly full-text articles were assessed for inclusion according to eligibility criteria. Studies with novel gene variants or epigenetic regulatory mechanisms in patients that underwent epilepsy surgery, with histopathological diagnosis of FCD type I or II according to Palmini's or the ILAE classification system, were included. Data were extracted and summarized for an overview of evidence.Results: Of 1,156 candidate papers, 39 met the study criteria and were included in this review. The advent of next-generation sequencing enabled the detection in resected FCD tissue of low-level brain somatic mutations that occurred during embryonic corticogenesis. The mammalian target of rapamycin (mTOR) signaling pathway, involved in neuronal growth and migration, is the key player in the pathogenesis of FCD II. Somatic gain-of-function variants in MTOR and its activators as well as germline, somatic, and second-hit mosaic loss-of-function variants in its related repressors have been reported. However, the genetic background of FCD type I remains elusive, with a pleomorphic repertoire of genes affected. DNA methylation and microRNAs were the two epigenetic mechanisms that proved to have a functional role in FCD and may represent molecular biomarkers.Conclusion: Further research into the possible pathogenic causes of both FCD subtypes is required, incorporating single-cell DNA/RNA sequencing as well as methylome and proteomic analysis. The collected data call for an integrated clinicopathologic and molecular genetic diagnosis in current practice not only to improve diagnostic accuracy but also to guide the development of future targeted treatments.

17 April 2018 in The Neuroradiology Journal
Verified
Journal Article
Closed access
OGOrlando Galego
Orlando Galego
JJJoana Jesus-Ribeiro
Joana Jesus-Ribeiro
MBMariana Baptista
Mariana Baptista
JSJoão Sargento-Freitas
João Sargento-Freitas
AMAna Inês Martins
Ana Inês Martins
EMEgídio Machado
Egídio Machado
Cerebral edema is frequent in patients with acute ischemic stroke (AIS) who undergo reperfusion therapy and is associated with high mortality. The impact of collateral pial circulation (CPC) status on the development of edema has not yet been determined. We studied consecutive patients with AIS and documented M1–middle cerebral artery (MCA) and/or distal internal carotid artery (ICA) occlusion who underwent reperfusion treatment. Edema was graded on the 24-hour non-contrast computed tomography (NCCT) scan. CPC was evaluated at the acute phase (≤6 hours) by transcranial color-coded Doppler, angiography and/or CT angiography. We performed an ordinal regression model for the effect of CPC on cerebral edema, adjusting for age, baseline National Institutes of Health Stroke Scale, Alberta Stroke Program Early Computed Tomography Score (ASPECTS) on admission, NCCT, parenchymal hemorrhagic transformation at 24 hours and complete recanalization at six hours. Among the 108 patients included, 49.1% were male and mean age was 74.2 ± 11.6 years. Multivariable analysis showed a significant association between cerebral edema and CPC status (OR 0.22, 95% CI 0.08–0.59, p = 0.003), initial ASPECTS (OR 0.72, 95% CI 0.57–0.92, p = 0.007) and parenchymal hemorrhagic transformation (OR 23.67, 95% CI 4.56–122.8, p < 0.001). Poor CPC is independently associated with greater cerebral edema 24 hours after AIS in patients who undergo reperfusion treatment.

1 January 2018 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
ICInês Martins Malva Correia
Inês Martins Malva Correia
JRJoana Jesus Ribeiro
Joana Jesus Ribeiro
LILuís Isidoro
Luís Isidoro
SBSonia Batista
Sonia Batista
CNCarla Nunes
Carla Nunes
LSLívia Sousa
Lívia Sousa

13 November 2017 in European Neurology
Verified
Journal Article
Closed access
PDF file
MSMário Sousa
Mário Sousa
FMFradique Moreira
Fradique Moreira
JJJoana Jesus-Ribeiro
Joana Jesus-Ribeiro
IMInês Marques
Inês Marques
FCFlávia Cunha
Flávia Cunha
CJCristina Januário
Cristina Januário
Background/Aims: Apathy is one of the most frequent, disabling and difficult-to-treat symptoms that show up in many neurodegenerative disorders. The aim of this study was to assess and compare apathy profile in Parkinson’s and Huntington’s patients using the same comprehensive instruments to measure apathy, cognition and depressive symptoms. Materials and Methods: We consecutively assessed Parkinson’s disease (PD) and Huntington’s disease (HD) patients recruited from a Movement Disorders Unit. In all patients, information related to demographics, clinical data, motor score (Movement Disorders Society-Unified Parkinson Disease Rating Scale; Unified Huntington Disease Rating Scale), cognition (Montreal Cognitive Assessment scale), depressive symptoms (Beck Depression Inventory II) and apathy (Apathy Evaluation Scale – clinical version) was collected. Patients with dementia or major depression according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revised criteria were excluded from the study. Results: Seventy-five patients were enrolled, 45 with PD and 30 with HD. Apathy was present in 42.5% of PD patients and 51.7% of HD patients. In PD patients, apathy was associated with motor score, shorter duration of disease, lower dose of levodopa equivalent daily dose and depressive symptomatology, whereas in HD patients, apathy was related to disease duration, motor score and cognitive impairment. Conclusions: We found a similar prevalence of apathy in PD and HD patients but with different clinical correlations and different apathy domains involved, and this may warrant the development of different therapeutic approaches.